ASCO Adds Jaw Osteonecrosis Recommendations to Bisphosphonate Guideline
Executive Summary
The American Society of Clinical Oncology's updated guideline for the use of bisphosphonates in patients with multiple myeloma warns of osteonecrosis of the jaw as a potential adverse effect, and agrees with the recommendations in revised FDA labels for the bone-strengthening drugs